Form 4: Tvardi Therapeutics Director Cynthia Smith Granted Stock Options

Director Cynthia Smith of Tvardi Therapeutics, Inc. was granted stock options to purchase 12,000 shares of common stock.

Summary

• On April 17, 2025, Cynthia Smith, a director of Tvardi Therapeutics, Inc., was granted stock options to purchase 12,000 shares of the company's common stock at an exercise price of $17.04 per share.
• The options vest in 12 equal quarterly installments over three years, beginning on July 17, 2025, contingent upon Ms. Smith's continuous service.
• Following the transaction, Ms. Smith directly owns 12,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a routine event and generally viewed as a positive incentive for the director.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain talent, aligning the interests of employees and directors with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of three years with quarterly installments is also a typical arrangement.
• Comparable companies such as Amgen, Gilead Sciences, and Biogen often use similar stock option plans to incentivize their directors and executives.

Stakeholder Impact

• The granting of stock options could potentially increase shareholder value if the director's performance leads to company growth.

Key Dates

Keywords

stock options, director, Tvardi Therapeutics, beneficial ownership, Form 4, TVRD, equity securities